Progressive external ophthalmoplegia (PEO) is a rare neurological disorder characterized by paralysis of the muscles that control eye movement, resulting in limited eye movement and, in some cases, facial asymmetry. The disorder is hereditary and is caused by mutations in mitochondrial and nuclear genes, resulting in mitochondrial dysfunction, which results in insufficient energy in cells, particularly in the neurons that control the eye. The main symptoms of PEO include gradual loss of eye movement, changes in oculomotor muscle function, double vision, and visual impairment. Additional neurological symptoms, such as limb weakness and progressive myopathy, may also develop over time.
History of the disease and interesting historical facts
Progressive external ophthalmoplegia was first described in 1888 by the German ophthalmologist and neurologist Albert Wagner. This description emphasized the progressive nature of the disease as well as the typical clinical manifestations. During the 20th century, attention to PEO increased with the growth of research into hereditary diseases and mitochondrial disorders. Interestingly, PEO is often associated with mitochondrial myopathy, indicating the need for a comprehensive approach to the diagnosis and treatment of mitochondrial diseases in general. By the mid-20th century, the main genetic links to the disease were identified, and research in the 1970s and 1980s showed that the condition can be progressive and hereditary, with a variety of clinical manifestations.
Epidemiology
According to modern research, the prevalence of progressive external ophthalmoplegia is approximately 1 in 100,000 people. However, this disease is often under-reported and may therefore be underestimated in medical statistics. This rare condition is more common in men, but cases have been reported in both women and children. The disease can begin at different ages, but most often begins in adulthood. Since PEO belongs to the group of mitochondrial diseases, its prevalence is largely due to ethnic and geographic factors that determine genetic predisposition.
Genetic predisposition to this disease
Progressive external ophthalmoplegia is caused by mutations in mitochondrial and nuclear genes. The most well-known is the MT-TL1 gene, which is responsible for the synthesis of mitochondrial tRNA, which is involved in various protein synthesis processes. Other genes involved include MT-ND1, MT-ND2, and MT-ATP6, which are responsible for the synthesis of proteins necessary for the normal functioning of the mitochondrial respiratory chain. Mutations in these genes lead to energy deficiency in the cell, which in turn causes degeneration of neurons responsible for eye muscle activity. It is important to note that PEO can be inherited either maternally due to mitochondrial inheritance or in an autosomal recessive manner.
Risk factors for the development of this disease
Among the risk factors for the development of progressive external ophthalmoplegia are the following:
- Heredity: Having relatives with similar neurological diseases increases the risk.
- Environmental factors: Exposure to certain toxic substances may increase the likelihood of developing the disease.
- Age: Risk increases with age, with the highest incidence of cases diagnosed between 20 and 40 years of age.
- Gender: High excess of cases among males compared to females.
- Circulation of infectious diseases: the presence of viral or bacterial infections that can affect the nervous system.
Diagnosis of this disease
Diagnosis of progressive external ophthalmoplegia requires a comprehensive approach and includes the following steps:
- Main symptoms:
- Paralysis of extraocular muscles.
- Double vision, accommodation disorder.
- Facial asymmetry if the facial nerves are involved.
- Laboratory tests:
- Genetic analysis for the presence of mutations in mitochondrial genes.
- Biochemical tests to assess mitochondrial function.
- Radiological examinations:
- Magnetic resonance imaging (MRI), which can help rule out other neurological diseases.
- Other types of disease diagnostics:
- Electroneuromyography (ENMG) to assess nerve conduction.
- Differential diagnosis:
- Conditions such as myasthenia gravis, Miller Fisher syndrome and other neurological disorders must be excluded.
Treatment
Treatment of progressive external ophthalmoplegia is a multi-step process, including:
- General treatment:
- Supportive therapy to improve the patient's quality of life.
- Physiotherapy to maintain muscle function and prevent contractures.
- Pharmacological treatment:
- Using creatine to increase cellular energy levels.
- Coenzyme Q10, which may improve mitochondrial function.
- Surgical treatment:
- In some cases, correction of eye positioning may be considered when there is significant impairment of extraocular muscle function.
- Other types of treatment:
- Psychological support and counseling, especially in cases where the disease causes significant stress.
List of medications used to treat this disease
There are a number of drugs that could be useful in the treatment of progressive external ophthalmoplegia:
- Creatine.
- Coenzyme Q10.
- Levocarnitine.
- B vitamins.
- Antioxidants.
Disease monitoring
Monitoring of progressive external ophthalmoplegia includes regular neurological examinations, as well as monitoring of symptom dynamics and response to treatment. The prognosis for patients may vary depending on genetic predisposition and severity of the disease. Possible complications may include progression of neurological symptoms, which may impede movement and daily activities. The likelihood of developing comorbidities such as depression and anxiety disorders is also high.
Age-related features of the disease
PNO manifests itself differently depending on the age group:
- In children: Symptoms may develop more quickly, but the disease may have an initial form with less severity.
- In adults: It often begins in adulthood, with progressive symptoms that cause significant difficulties in daily life.
- In older people: the risk of symptom progression increases, which can significantly complicate treatment and care.
Questions and Answers
- What are the main symptoms of progressive external ophthalmoplegia? The main symptoms include paralysis of the extraocular muscles, double vision and asymmetry of the facial muscles.
- How is PNO diagnosed? Diagnosis includes genetic tests, MRI and electrodiagnostics, as well as symptom analysis.
- What genes are involved in the development of PNO? Mutations in the MT-TL1, MT-ND1, and MT-ATP6 genes are associated with this condition.
- What are the treatment options for PND? Treatment may include creatine therapy, coenzyme Q10, and supportive physical therapy.
- What is the prognosis for patients with PNO? Prognosis varies; many patients can maintain a normal quality of life with supportive care, but progression of symptoms is possible.
